Latest in News & Research

Adverse Event Risk Up for >90 Days Versus >30 Days of Corticosteroids for Eczema

Authors suggest limiting duration of oral corticosteroid treatment to 90 days or less to reduce risk of adverse effects

By Lori Solomon (HealthDay News) | | July 24, 2024

Do Surgical Margins Affect the Risk of Recurrence in Cutaneous SCCs of the Scalp?

Risk of recurrence up for tumors that present concurrent invasion of the galea aponeurotica and close deep margins

By Dermsquared Editorial Team | | July 24, 2024

Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adult

Hispanic and non-Hispanic Black sexual minority males and females have higher rates of skin cancer than their heterosexual counterparts

By Elana Gotkine (HealthDay News) | | July 19, 2024

Air Pollution Exposure Tied to New Psoriasis

Increase in psoriasis risk also seen among those with higher genetic vulnerability and increased exposure to air pollutants

By Lori Solomon (Healthday News) | | July 18, 2024

Subsequent Skin Cancer Risk Increased for Stem Cell Transplant Recipients

Risk factors for skin cancer include chronic graft-versus-host-disease, male gender, voriconazole exposure

By Dermsquared Editorial Team | | July 17, 2024

Cendakimab Effective for Moderate-to-Severe Atopic Dermatitis

Significant reduction seen in primary end point of mean percentage change in EASI score from baseline to week 16 with 720 mg once weekly

By Dermsquared Editorial Team | | July 17, 2024

Direct CGRP Inhibition Cuts Acne, Rosacea in Patients With Migraine

Significantly reduced rate of acne and rosacea seen in patients treated with CGRPi mAbs versus triptans, topiramate

By Elana Gotkine (HealthDay News) | | July 16, 2024

CDC Reports Seven Cases of Illness After Possible Counterfeit Botox Injections

Four of the cases, identified in Tennessee, received counterfeit botulinum neurotoxin, administered by unlicensed individual

By Elana Gotkine (Healthday News) | | July 12, 2024

FDA Approves Zoryve for Atopic Dermatitis

The once-daily, nonsteroidal cream is approved for adults and children 6 years and older

By Lori Solomon (Healthday News) | | July 11, 2024

Distinct Recurrence Patterns Seen for Primary, Relapsed Cutaneous Melanoma

Significantly lower progression-free survival, reduced distant metastasis-free survival seen for BRAF-mutated CM with immune checkpoint inhibitor

By Dermsquared Editorial Team | | July 10, 2024

Sustained Safety, Efficacy Seen for Dupilumab in Atopic Dermatitis

Sustained benefit seen for adults with moderate-to-severe AD during five-year open-label extension study

By Dermsquared Editorial Team | | July 10, 2024

Adherence to Mediterranean Diet, Omega-3 Fatty Acids Beneficial in Acne

Reduction seen in inflammatory and noninflammatory lesions, improvement seen in overall quality of life with EPA/DHA

By Elana Gotkine (HealthDay News) | | July 10, 2024

Comprehending Compensation: A Dermatologist’s Definitive Guide to Navigating Job Offers, Pay Structure, Benefits & More!

As a dermatologist, your journey through medical school and residency has equipped you with the expertise to diagnose and treat more than 3,000 skin,...

By myDermRecruiter | | July 09, 2024

Rural Residents Continue to Have Higher Odds of Skin Cancer

Rural-urban differences magnified by lower income and race

By Elana Gotkine (HealthDay News) | | July 09, 2024

Satisfaction With Hair Growth Seen With Ritlecitinib in Alopecia Areata

Proportion of patients allocated to ritlecitinib who were satisfied increased or was maintained at week 48

By Dermsquared Editorial Team | | July 01, 2024

Rules-Based Triage System Improves Patient Stratification for Skin Cancer

Three high-risk lesion groups seen faster in the new triage pathway, with a mean reduction of 26 days

By Dermsquared Editorial Team | | July 01, 2024

Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue

Increasing joint pain intensity associated with overall fatigue in patients with psoriasis with or without psoriatic arthritis

By Elana Gotkine (HealthDay News) | | July 01, 2024

Few Patients With Positive Margins After Basal Cell Excision Have Recurrence

Recurrence developed in more patients who did not receive additional treatment and in fewer receiving nonsurgical treatments

By Elana Gotkine (HealthDay News) | | July 01, 2024

RVUs vs. Collections in Dermatology: Understanding Productivity and Revenue Metrics for Dermatologists

Understanding RVUs (Relative Value Units) and collections is crucial for dermatologists as these metrics play a significant role in how your compensation and productivity...

By myDermRecruiter | | June 28, 2024

Study Identifies Prognostic Factors for Localized Adnexal Carcinomas

Radiotherapy only associated with longer progression-free survival in patients with unresectable locally advanced or metastatic tumors

By Elana Gotkine (HealthDay News) | | June 26, 2024

Low Recurrence Seen for Excision of Melanoma in Situ With 5-mm Margin

99.1 percent of the 351 MISs identified from 292 patients did not have clinical recurrence after excision

By Elana Gotkine (HealthDay News) | | June 26, 2024

Abrocitinib Effective, Tolerated for Prurigo Nodularis, Chronic Pruritus

Decrease in Peak Pruritus Numeric Rating Scale for PN, chronic pruritus of unknown origin patients

By Elana Gotkine (HealthDay News) | | June 25, 2024

Nonsignificant Survival Benefit Seen for Dabrafenib, Trametinib in Melanoma

Consistent survival benefit seen across several prespecified subgroups, including those with a BRAFV600E mutation

By Elana Gotkine (HealthDay News) | | June 24, 2024

24 of 1200

Headline from the Week of February 09 - 15, 2026

Second Annual National Cancer Database Report Presented for 2022

By Elana Gotkine (HealthDay News) | | February 11, 2026

Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

By Elana Gotkine (HealthDay News) | | February 11, 2026